Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

被引：11

作者：

Shah, Nina ^{[1
]}

Thall, Peter F. ^{[2
]}

Milton, Denai R. ^{[3
]}

Bashir, Qaiser ^{[1
]}

Parmar, Simrit ^{[1
]}

Lin, Pei ^{[4
]}

Kebriaei, Partow ^{[1
]}

Nieto, Yago ^{[1
]}

Popat, Uday R. ^{[1
]}

Hosing, Chitra ^{[1
]}

Cornelison, Amanda ^{[5
]}

Delgado, Ruby ^{[1
]}

Shpall, Elizabeth J. ^{[1
]}

Orlowski, Robert Z. ^{[6
]}

Champlin, Richard E. ^{[1
]}

Qazilbash, Muzaffar ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Biostatist, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Biostatist, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA

[5] MD Anderson Canc Ctr, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood.V128.22.2269.2269

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2269

引用

页数：6